These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1825480)

  • 1. Phenotypic analysis of a resting subpopulation of human peripheral blood NK cells: the FcR gamma III (CD16) molecule and NK cell differentiation.
    Warren HS; Skipsey LJ
    Immunology; 1991 Jan; 72(1):150-7. PubMed ID: 1825480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
    Heiskala M; Ståhls A; Seppälä I; Timonen T
    Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of human FcRIII-positive and negative natural killer cells.
    Nagler A; Lanier LL; Cwirla S; Phillips JH
    J Immunol; 1989 Nov; 143(10):3183-91. PubMed ID: 2530273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
    Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
    Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of cloned human natural killer cells via Fc gamma RIII.
    Werfel T; Uciechowski P; Tetteroo PA; Kurrle R; Deicher H; Schmidt RE
    J Immunol; 1989 Feb; 142(4):1102-6. PubMed ID: 2464637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A subset of CD16-natural killer cells without antibody-dependent cellular cytotoxicity function.
    Schubert J; Heiken H; Jacobs R; Delany P; Witte T; Schmidt RE
    Nat Immun Cell Growth Regul; 1990; 9(2):103-11. PubMed ID: 2141105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells.
    Saito S; Morii T; Enomoto M; Sakakura S; Nishikawa K; Narita N; Ichijo M
    Cell Immunol; 1993 Dec; 152(2):605-13. PubMed ID: 7504983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of activation-induced CD45RO with maintenance of CD45RA expression during prolonged culture of T cells and NK cells.
    Warren HS; Skipsey LJ
    Immunology; 1991 Sep; 74(1):78-85. PubMed ID: 1834549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone.
    Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K
    J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-induced expression of Fc gamma RIII (CD16) on human monocytes.
    Phillips JH; Chang CW; Lanier LL
    Eur J Immunol; 1991 Apr; 21(4):895-9. PubMed ID: 1826887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
    Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
    van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
    J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the Fc mu receptor on human natural killer cells. Interaction with its physiologic ligand, human normal IgM, specificity of binding, and functional effects.
    Pricop L; Rabinowich H; Morel PA; Sulica A; Whiteside TL; Herberman RB
    J Immunol; 1993 Sep; 151(6):3018-29. PubMed ID: 7690792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-8 production by CD16-CD56bright natural killer cells in the human early pregnancy decidua.
    Saito S; Kasahara T; Sakakura S; Enomoto M; Umekage H; Harada N; Morii T; Nishikawa K; Narita N; Ichijo M
    Biochem Biophys Res Commun; 1994 Apr; 200(1):378-83. PubMed ID: 7513162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
    Gaddy J; Broxmeyer HE
    Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor.
    Harris DT; Travis WW; Koren HS
    J Immunol; 1989 Oct; 143(7):2401-6. PubMed ID: 2528593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
    Ellis TM; Creekmore SP; McMannis JD; Braun DP; Harris JA; Fisher RI
    Cancer Res; 1988 Nov; 48(22):6597-602. PubMed ID: 2902918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.
    Bowles JA; Weiner GJ
    J Immunol Methods; 2005 Sep; 304(1-2):88-99. PubMed ID: 16109421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.